• Policy
• Daewoong has added a line-up of osteoporosis treatments PO
• by Lee, Tak-Sun Aug 3, 2021 08:27pm

• Policy
• The number one treatment for mild COVID is Kaletra
• by Kim, Jung-Ju Aug 3, 2021 08:24pm

• Company
• Will regulations on ERP be established?
• by Aug 3, 2021 08:24pm

• Policy
• Pfizer aims to commercialize PF-07321332 by the end of 2021
• by Lee, Tak-Sun Aug 3, 2021 08:09pm

• Company
• Samsung launches Humira Biosimilar ‘Adalloce’ in Korea
• by Eo, Yun-Ho Aug 3, 2021 07:04am

• Policy
• Peramivir has earned its generic exclusivity
• by Lee, Tak-Sun Aug 2, 2021 08:41pm

• Company
• Beijing Hanmi's 2Q operating profit increased by 50%
• by Chon, Seung-Hyun Aug 2, 2021 08:37pm

• Policy
• Reimbursement criteria for Cosentyx and Taltz inj. expanded
• by Kim, Jung-Ju Aug 2, 2021 06:06am

• Company
• ACRC "Hemlibra's reimb. standards need to be reexamined"
• by Kim, Jin-Gu Aug 2, 2021 06:05am

• Company
• Daewoong recovers with record 2Q sales of ₩289.7 billi
• by An, Kyung-Jin Jul 30, 2021 05:48am